Tel. +41 61 295 50 02annett. altvater@baselarea. swiss
The biopharmaceutical company SunRegen Healthcare develops a therapy for neurodegenerative eye diseases like Optic Atrophy. The two co-founders and managers Dr. Yuhong Dong and Mr. David Guan moved their young startup to the Switzerland Innovation Park Basel Area in Allschwil in January 2019.
In 2020 they hope to reach the next milestone and move their project from preclinical to clinical stage for their lead compound SBC003. This synthetic molecule is derived from a natural active ingredient that can be found in a medical herb used in the oriental medicine. Yuhong and David plan to test their compound for ALS as another target indication. Further, they want to test SBC003 for other neurological and neuromuscular diseases such as Alzheimer’s, Parkinson’s or Huntington’s disease.
At the Switzerland Innovation Park Basel Area in Allschwil, the co-founders concentrate on developing their business. They are especially happy that they were able to move in and start working right from the beginning, thanks to the furnished office. To host visitors, they appreciate the coffee area that is open to all residents as well as the meeting rooms the Switzerland Innovation Park Basel Area offers. “Even before we could afford an office, the team at the Switzerland Innovation Park was very forthcoming. They are always very friendly – we really enjoy being here.”
SunRegen Healthcare is one of the participants of the first round of the BaseLaunch accelerator. Back in 2017, Yuhong and David reached Phase I of the program, benefitting from customized coaching and funding for three months. Although they were not selected for phase II, they persisted in building their startup. In 2018, they won the BIO-Europe 2018 Startup Slam Competition, held in Copenhagen and gained access to a top-tier mentoring program with industry experts from Johnson & Johnson.